Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
STAAR Surgical Company(STAA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for STAA
10/23/2026: STAA (3-star) is currently NOT-A-BUY. Pass it for now.
STAAR Surgical is a specialized medical device company recognized for its EVO Visian Implantable Collamer Lenses, which provide an alternative to laser-based vision correction. The company has a leading position in the phakic lens market, supported by proprietary material technology that has driven strong historical growth. Its primary investment story centers on the global adoption of its lenses, particularly as it expands in the United States and emerging markets. However, investors must consider risks including intense competition from large eye-care conglomerates, the elective nature of the surgery, and potential valuation volatility. This stock may suit growth-oriented investors who can tolerate the risks associated with elective medical procedures and market-wide adoption cycles.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company focuses on expanding its specialized refractive lens business into new global markets. |
| Momentum investor | Mixed fit | Performance is highly dependent on clinical adoption trends and requires a positive uptake signal. |
| Value investor | Weak fit | The stock often trades at a premium multiple reflecting its growth profile rather than current earnings yield. |
| Dividend investor | Weak fit | The company does not pay a dividend, focusing all capital on reinvestment. |
| Low-risk investor | Weak fit | High market volatility and dependence on elective procedures make this a higher-risk profile. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings based on quarterly sales reports and market sentiment. |
| Valuation risk | Medium / high | High growth expectations are already baked into the share price, leaving little room for error. |
| Competition risk (laser surgery providers) | High | Advancements in LASIK and other laser techniques represent a direct threat to the ICL business model. |
| Business quality | Medium | The company has a strong proprietary technology but is smaller and less diversified than industry incumbents. |
| Dividend income | Low / none | The company provides no income to shareholders through dividends. |
| Execution risk | Medium / high | Failure to effectively scale global sales and training could limit growth projections. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 75.61% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio 281.12 | 1Y Target Price 27.67 |
Price to earnings Ratio 281.12 | 1Y Target Price 27.67 | ||
Volume (30-day avg) 881.8K shares | Beta 1.18 | 52 Weeks Range 15.59 - 35.87 | Updated Date 10/23/2026 |
52 Weeks Range 15.59 - 35.87 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Refractive Products | Sales of the EVO Visian ICL line and related lens accessories. | The vast majority of revenue comes from people choosing ICL surgery to fix their vision. |
| Cataract/Other | Traditional IOLs and surgical instruments. | This is a smaller, legacy part of the business that complements the main refractive focus. |
| Geography | Significant sales across China, North America, and Europe. | The company relies on international markets for a major portion of its growth. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 281.12 | Forward PE 62.5 | Enterprise Value 1.20B | Price to Sales(TTM) 3.32 |
Enterprise Value 1.20B | Price to Sales(TTM) 3.32 | ||
Enterprise Value to Revenue 5.36 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 50.14M | Shares Floating 26.13M |
Shares Outstanding 50.14M | Shares Floating 26.13M | ||
Percent Insiders 0.85 | Percent Institutions 111.59 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.